PWWP2B: A Potential Drug Target and Biomarker (G170394)

Target Name: PWWP2B

NCBI ID: G170394

PWWP2B

PWWP2B: A Potential Drug Target and Biomarker

Purine World War 2 B (PWWP2B) is a protein that is expressed in the urine and plasma of individuals with urinary tract infections (UTIs) and other conditions that affect the balance of phosphate and purine levels in the body. PWWP2B has been identified as a potential drug target and biomarker for several reasons.

Firstly, PWWP2B is a key regulator of the balance of phosphate and purine levels in the body. It is a protein that is involved in the regulation of phosphate and purine homeostasis, which is critical for maintaining the health and function of many different cell types in the body. Disruptions in the balance of phosphate and purine levels can have serious consequences for the health of these cells, including leading to the development of diseases such as urinary tract infections, kidney stones, and bone loss.

Secondly, PWWP2B is a potent inhibitor of the enzyme alkaline phosphatase, which is responsible for breaking down phosphate and purine ions in the body. This means that when levels of phosphate and purine are imbalanced, PWWP2B can inhibit the activity of alkaline phosphatase, which can help to maintain the balance of phosphate and purine ions in the body.

Thirdly, PWWP2B is a potential biomarker for several types of UTIs. UTIs are common infections that can cause severe burns, abdominal pain, and fever. They are typically treated with antibiotics, which can disrupt the balance of phosphate and purine levels in the body. By monitoring the levels of PWWP2B in the urine and plasma of individuals with UTIs, researchers may be able to determine the effectiveness of different treatments and monitor the impact of these treatments on the body's overall balance of phosphate and purine ions.

Finally, PWWP2B is a potential drug target for several different types of cancer. Cancer cells often have altered levels of phosphate and purine ions in the body, which can contribute to their growth and survival. Researchers are currently studying the potential therapeutic benefits of targeting PWWP2B in cancer cells.

In conclusion, PWWP2B is a protein that is expressed in the urine and plasma of individuals with urinary tract infections and other conditions that affect the balance of phosphate and purine levels in the body. It is a potential drug target and biomarker for several reasons, including its involvement in the regulation of phosphate and purine homeostasis, its ability to inhibit the activity of alkaline phosphatase, its potential as a biomarker for UTIs, and its potential as a drug target for cancer. Further research is needed to fully understand the role of PWWP2B in the treatment of UTIs and other conditions that affect phosphate and purine levels in the body.

Protein Name: PWWP Domain Containing 2B

Functions: Chromatin-binding protein that acts as an adapter between distinct nucleosome components (H3K36me3 or H2A.Z) and chromatin-modifying complexes, contributing to the regulation of the levels of histone acetylation at actively transcribed genes (PubMed:30228260). Competes with CHD4 and MBD3 for interaction with MTA1 to form a NuRD subcomplex, preventing the formation of full NuRD complex (containing CHD4 and MBD3), leading to recruitment of HDACs to gene promoters resulting in turn in the deacetylation of nearby H3K27 and H2A.Z (PubMed:30228260). Plays a role in facilitating transcriptional elongation through regulation of histone acetylation (By similarity). Negatively regulates brown adipocyte thermogenesis by interacting with and stabilizing HDAC1 at the UCP1 gene promoter, thereby promoting histone deacetylation at the promoter leading to the repression of UCP1 expression (By similarity)

The "PWWP2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PWWP2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets